Latest Safety News

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.

OD6 Metals reports significant metallurgical advancements at its Splinter Rock Rare Earth Project, integrating Ion Exchange technology to enhance impurity removal and increase recovery rates. These improvements promise to materially improve project economics and broaden market appeal.

xReality Group’s US subsidiary Operator XR has landed its largest order yet, a $5.7 million contract to supply VR training systems to the Texas Department of Public Safety, marking a significant milestone in its US expansion.

Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

After four years on Colorado’s I-70 Vail Pass, EdenCrete® concrete shows markedly superior durability compared to standard and silica fume mixes, signaling a potential shift in high-altitude road construction.

Amplia Therapeutics reports encouraging interim results from its ACCENT trial, with its drug narmafotinib improving progression-free survival and response rates in advanced pancreatic cancer.

Charter Hall Long WALE REIT reports a $118.3 million statutory profit for FY25, reversing last year's heavy loss, while maintaining stable distributions and actively managing debt facilities.

Horseshoe Metals advances its Horseshoe Lights copper-gold project with mining approval secured, site mobilization underway, and new drilling planned to expand resources.

Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.